Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology by András Inotai et al.
Inotai et al. BMC Health Services Research 2012, 12:332
http://www.biomedcentral.com/1472-6963/12/332RESEARCH ARTICLE Open AccessAttempt to increase the transparency of fourth
hurdle implementation in Central-Eastern
European middle income countries: publication of
the critical appraisal methodology
András Inotai1*, Márta Pékli2, Gabriella Jóna2, Orsolya Nagy2, Edit Remák3 and Zoltán Kaló4,5Abstract
Background: In middle income countries the number of trained health technology assessment specialists is limited
and the public budget for health technology assessment is considerably lower compared to developed countries.
These countries therefore must develop their own solutions to improve the quality and efficiency of health
technology assessment implementation in reimbursement decisions. Our study aimed to develop a scientifically
rigorous and detailed appraisal checklist for economic evaluations of pharmaceuticals in the single health
technology assessment process.
Methods: The research design entailed a review of economic evaluations, submitted for reimbursement of
pharmaceuticals, by two independent academic reviewers to identify the most common methodological problems.
Fifty economic evaluations submitted in 2007-2008, randomly selected by the Health Technology Assessment Office
served as data sources. The new checklist was developed by an iterative working process: first by assessing ten
economic evaluations, then improving the checklist by generating new question items, then employing the
improved checklist to assess the next ten economic evaluations. After appraising 25 documents, the reviewers
reconciled their opinions and improved the checklist with the researchers of the Health Technology Assessment
Office during an expert panel discussion. The reviewers scrutinized the second 25 economic evaluations, after
which the expert panel finalized the checklist with consensus.
Results: The final checklist consists of 91 yes or no questions in 11 main topics concerning comparator selection,
efficacy, effectiveness, costs, sensitivity analysis, methodological approach, transparency, and interpretation of
results. The new checklist is based on current Hungarian evaluation practice. As the published checklist will be part
of the official single health technology assessment process of pharmaceuticals, submitters will be able to assure the
quality of their economic evaluation.
Conclusions: The transparent critical appraisal method should improve the consistency of pharmaceutical
reimbursement decisions and facilitate the utilization of economic evaluations in other fields of health care
decision-making in other Central-Eastern European countries.* Correspondence: inotai.andras@gytk.sote.hu
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Compared to high-income European countries, middle
income Central and Eastern European (CEE) countries
have worse health status [1,2]. To improve the health of
population, these countries have even more limited
resources than Western European countries. As the
value based price of innovative health technologies is
adjusted to top 5 European countries, the price is often
relatively too high in countries with lower income [3].
Consequently the need for justification of cost-
effectiveness for expensive technologies is even greater
in CEE countries. Unfortunately the number of trained
health economists and health technology assessment
(HTA) specialists is limited and the public budget for
HTA is lower than in developed countries [4-6]. There-
fore middle income countries must develop their own
solutions to improve the quality and efficiency of HTA
implementation in reimbursement decisions.
The first necessity is a development of a guideline for
economic evaluations. It is, however, difficult to develop
guideline which is perfectly relevant for all different kind
of health technologies and services. For example, the
HTA approach for medical devices is different from
pharmaceuticals due to the limited availability of rando-
mised controlled trials (RCTs), and other methodological
problems such as multiple indications, frequent product
modifications, learning curves, and high fixed cost [7].
HTA guidelines are usually broad enough to cover all
different aspects [8,9], however the National Institute for
Health and Clinical Excellence also developed focused
guidelines for diagnostics [10] and devices [11].
The second necessity of quality assurance in HTA is
the use of critical appraisal checklists especially in those
countries where single HTA process is implemented. In
the current examples of this process this means that the
manufacturer of the technology prepares the assessment
of the technology. The public HTA office cannot prepare
an independent assessment (double technology assess-
ment) and is only responsible for the critical appraisal of
the submitted material. In countries with single HTA
process, the most critical question is how to ensure the
appropriateness, the homogeneity and the transparency
of the critical appraisal. There are two different
approaches: The first focuses on the transparent descrip-
tion of the appraisal methodology, the second focuses
more on disclosing details of each individual case. As
submissions may contain confidential information (i.e.
proposed price of the technology), the first approach can
be easily implemented in any countries.
There are many available international checklists
[12-15], however, they are often not detailed enough to
address specificities of long HTA submissions or not
adjusted to the country specific methodological pro-
blems. Therefore authors suggest that for criticalappraisal of single technology assessment, detailed coun-
try and technology specific checklists should be devel-
oped based on the review of existing local HTA practices.
In Hungary cost-effectiveness and budget impact ana-
lyses have been mandated in the reimbursement process
of new pharmaceuticals since 2003. Guidelines for eco-
nomic evaluations were published [16] in 2002, but have
never been updated. These guidelines covered all health
care interventions therefore they were not specific for
pharmaceuticals and not targeted to reimbursement
questions. The first six years experience of mandatory
fourth hurdle (i.e. local cost-effectiveness evidence) for
new pharmaceuticals indicated that the quality of eco-
nomic evaluations submitted in pharmaceutical reim-
bursement dossiers and the quality of critical appraisal
by the HTA Office varied considerably. Similar trends
have been observed in Canada [17], Latin America [18],
and Sweden [19].
Therefore in 2009, an expert panel was established to
develop a detailed, publicly available, scientifically rigor-
ous, and policy-relevant Hungarian critical appraisal
checklist to improve the quality of economic evaluations
and budget impact analyses submitted for single health
technology assessment in pharmaceutical reimburse-
ment applications and to reduce the heterogeneity of
appraisals. This paper describes the methodological ap-
proach of checklist development, and presents the final
checklist.
Methods
The expert panel consisted of two independent academic
experts, who scrutinized previous submissions and
developed a new draft checklist, and members of the
HTA Office who supervised the project and approved
new items in the checklist. To maintain the full support
of decision-makers in the Ministry of Health and the
National Health Insurance Fund the project had no
intention to revise or comment on previous reimburse-
ment decisions. Overall, 50 consecutive economic eva-
luations that had been submitted for reimbursement of
pharmaceuticals in 2007-2008 were selected by the HTA
Office to be scrutinized by the two independent aca-
demic reviewers for the most common methodological
problems. The first ten submissions were assessed using
the previously translated Critical Appraisal Skills
Programme (CASP) questionnaire [20] in the form of a
spreadsheet independently completed by each reviewer.
In the process, several new items were added to reflect
common methodological or technical problems. The
spreadsheet included a column listing the questions
from the new checklist (one per row), and each eco-
nomic evaluation had a separate column to record the
reviewers’ answers and comments. The assessments of
the first ten submissions were then reconciled by the
Inotai et al. BMC Health Services Research 2012, 12:332 Page 3 of 7
http://www.biomedcentral.com/1472-6963/12/332reviewers. The format of the CASP checklist was also
changed; as many of the new question items were not
relevant for all submitted economic evaluations, a “not
relevant” option was added to “yes” or “no” option. For
the next ten submissions, a draft version of the new
extended checklist was employed (Figure 1). Each new
technical problem observed generated a new question
item under the assumption that these questions could
prevent future occurrences of these problems. Conse-
quently, the development process was iterative: as an-
other generally applicable problem was identified the
reviewers added a new question item to the draft ques-
tionnaire. After 25 economic evaluations were assessed,
the opinions of the reviewers were again reconciled and
the checklist was revised through an expert panel dis-
cussion with the entire staff of the HTA Office. Subse-
quently, the reviewers scrutinized the second 25
economic evaluations, again extending the checklist
with further question items. The final checklist was
achieved through a consensus decision of the expert
panel.
The Hungarian Critical Appraisal Checklist is not a
scorecard; it only lists the most relevant questions for fa-
cilitating the appraisal process. While quantitative ques-
tionnaires (i.e., those with scoring) can be validated by
statistical methods, it is less obvious how to validate a
qualitative critical appraisal checklist. The development
process described here incorporated three steps to im-
prove validity. First, every new question item was incor-
porated only through consensus of the expert panel.
Second, in a 14-month probation period, between
September 2009 and November 2010, the checklist was
used by the public HTA office in the appraisal of 80 new
pharmaceutical reimbursement submissions. Researchers
of the HTA Office confirmed the appropriateness of the
checklist and reported no need for further amendments.
Finally, an independent opponent was given the oppor-


























Figure 1 Development of the checklist.during a two-hour meeting of the Hungarian Health
Economics Association dedicated to the public discus-
sion of the checklist. This followed an approach similar
to that of the Health Economist’s Study Group in the
United Kingdom [21].
Results
The final Hungarian Critical Appraisal Checklist
(Additional file 1) has two major themes: the first
addresses economic evaluations, whereas the second
concentrates on budget impact analyses. Economic eva-
luations are the subject of 80 yes or no questions in ten
major sections; 11 questions relate specifically to budget
impact analysis (see Table 1).
The ten sections addressing economic evaluations
cover core ideas related to the selection of comparators,
effectiveness, costs, sensitivity analysis, methodological
approach, transparency, and interpretation of results. To
reflect the possible variations in study design of eco-
nomic evaluations, separate alternative sections were
developed for cost-minimization analyses and modeling
approaches of cost-effectiveness analyses (including deci-
sion tree, Markov and simulation models). This separ-
ation allows the incorporation of methodology-specific
issues into the checklist. Interestingly, none of the 50 re-
imbursement dossiers reviewed included economic ana-
lyses conducted alongside prospective clinical trials; this
was mainly due to the fact that Hungary is too small
market for conducting adequately powered prospective
trials for local reimbursement purposes.
When the checklist is used for critical appraisal,
reviewers may exclude non-relevant question items. If
the problem raised by a question is relevant and has
been addressed appropriately in the economic analysis of
pharmaceuticals, the question should be answered “yes”.
If a “yes” answer cannot be justified in the case of a rele-
vant question, the response should be “no”. The authors



















Table 1 Structure of the checklist
Topic # of items
1. Economic Evaluation 80
1.1. Filter Questions 2
1.2. Research Question (relevance, comparator,
financing protocol)
2
1.3. Health Benefit 25
1.3.1. Source of Scientific Evidence 7
1.3.2. Evaluation of Relative Effectiveness in Case
of Indirect Comparison
10
1.3.3. Magnitude of Health Benefit 8
1.4. Cost 8
1.5. Time Horizon, Discounting 3
1.6 Alternative Sections for Methodology 22
1.6.1. Cost-Minimization Analysis 3
1.6.2. Cost Effectiveness Analyses 19
1.6.2.1. Decision Tree Model 4
1.6.2.2. Markov Model 7
1.6.2.3. Simulation Model 8
1.7. Decision Rule 3
1.8. Sensitivity Analysis 6
1.9. General Methodology: Adequacy and Transparency 5
1.10. Interpretation regarding the Economic Evaluation 4
2. Budget Impact Analysis 11
Total checklist 91
Inotai et al. BMC Health Services Research 2012, 12:332 Page 4 of 7
http://www.biomedcentral.com/1472-6963/12/332comments for all answers in the “explanation” column.
Sub-questions in brackets that follow some questions
also prompt explanations.
An important issue when developing checklists is
the distinction between the positive aspect of reporting
(e.g. did they apply discounting?) and normative aspects
of methods (e.g. did they discount by a rate of 5% per
annum in real terms?). We took an intermediate ap-
proach, in several cases we considered the normative
aspects without clarifying what is the only appropriate
approach (e.g. did they apply the appropriate discount
rate?), as the correct approach can be different for par-
ticular technologies.
In use, a higher proportion of “yes” answers would in-
dicate the appropriateness of the economic evaluation
and budget impact analysis for inclusion in the reim-
bursement dossier. However, the questions are not equal
and not weighted; therefore, the critical appraisal check-
list cannot transform the assessment of the quality of
the single technology appraisal into an automatic
process. There are twofold benefits from the checklist.
At first to guide those who prepare submissions on what
are the most critical methodological and technical ques-
tions of the HTA report, secondly to make sure that
these important factors are not missed in the criticalappraisal process, therefore the heterogeneity of apprai-
sals is reduced.
Discussion
Certain countries assure the quality of HTA in the reim-
bursement decision process by improving the details of
their guidelines; however in these cases the guideline
may not be relevant for all different technologies
(e.g. pharmaceuticals, medical devices, screening proce-
dures etc.). For middle income CEE countries with lim-
ited budget and capacity, general guidelines and detailed
supplementary checklists for each kind of health tech-
nologies could be an optimal solution. As a first step, we
presented a prototype how to prepare such a scientific-
ally rigorous appraisal tool specifically developed for
pharmaceutical technologies based on the quality assess-
ment of economic evaluations in previous reimburse-
ment dossiers. The existence of such tool, however,
could not substitute the overdue updating of the
Hungarian guidelines for economic evaluation or the de-
velopment of a Reference Guide to those making sub-
missions. Development of similar checklists for medical
devices or other medical technologies should also be
considered. Both the methodology of development and/
or the actual questions of the checklist might be of inter-
est for other CEE countries with single HTA to assure
the better use of economic evaluations in the reimburse-
ment of pharmaceuticals. For CEE countries where HTA
was recently introduced, this checklist could serve as a
draft to develop their own country specific question-
naire, with the adaptation of the iterative methodology
described in this paper.
This Hungarian checklist was developed to detect and
consequently to prevent potential methodological and
technical problems seen in economic evaluations in
pharmaceutical reimbursement submissions. Identifica-
tion of these issues requires advanced skills; thus,
authors want to emphasize how important the qualifica-
tions of the assessors are [22]. However, based on the 14
month probation period, such a detailed checklist is a
useful aid even for new and relatively inexperienced
associates of the HTA Office.
There is a trade-off between the sensitivity and simpli-
city of critical appraisal checklists (Table 2 compares
some well known international checklists with the
Hungarian Critical Appraisal Checklist). Shorter ques-
tionnaires are suitable for a rapid assessment of eco-
nomic evaluations, e.g., a review of scientific papers [23].
However, neither the shorter [24] nor the longer [15]
international critical appraisal checklists are detailed
enough to reliably filter all problems observed in health
economic analyses in reimbursement submissions of
pharmaceuticals, particularly as inappropriate decisions
by the authorities may result in serious health and
Table 2 Comparison of the Hungarian Critical Appraisal Checklist to some other international checklists













Number of questions 10 / 12 35 19 16 91




no no no yes no
Reference [20,24] [15,22] [14,22] [13,22] NA.
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questions seen on the shorter lists can be interpreted dif-
ferently, further eroding their usefulness for assessors. The
majority of existing questionnaires are based on the
current sophisticated skill set and practice of developed
countries, therefore may not be suitable in middle income
countries due to limited capacity of experts and hetero-
geneity of submissions. The time required to answer a
detailed questionnaire (such as the Hungarian Critical Ap-
praisal Checklist with 91 items) must be acknowledged,
but the thorough revision of data and methodology in a
public HTA appraisal requires several days for each sub-
mission anyway. In addition, compared with scientific
publications, economic evaluations in reimbursement sub-
missions are lengthier, and include more details about
assumptions, input data, and study methodology [25].
Some unique items of the Hungarian Critical Ap-
praisal Checklist should be highlighted. Specific ques-
tions are dedicated to therapeutic guidelines, the
financing protocol (i.e., whether the therapy is reim-
bursed for first-line use or only second- or third-line),
and the level of reimbursement (due to the complexity
of the Hungarian public financing system). Such ques-
tions were not common in previous checklists. Based on
50 submissions, a question is dedicated to prevent in-
appropriate selection of studies favouring the investiga-
tional technology. Assessment of relative effectiveness in
indirect comparison of pharmaceuticals has gained in-
creasing importance recently [26], as the comparator in
pivotal clinical trials may not be policy relevant in all
countries, e.g., the comparator may not be reimbursed
or widely used. As a consequence, ten specific questions
have been included to evaluate the methodology of rela-
tive effectiveness in case an indirect comparison is
employed in submissions. A recurring methodological
error was the calculation of daily therapeutic drug cost
from the perspective of the third-party payer. Unless the
full public price is employed in the calculation, the most
cost-effective scenario from the payer’s perspective
would be a 0% reimbursement, i.e., no increase in drug
costs with additional health gain. By requesting the
graphical structure and detailed description of decision
tree and Markov models and the transparent descriptionof all input data, the HTA Office should be able to re-
construct some of the economic models [27]. This prac-
tice prevents the assessment of cost-effectiveness based
on black box economic models, which was common ap-
proach previously. In some extreme submissions, a long
general introduction was accompanied by a brief eco-
nomic evaluation; therefore, a question was dedicated to
address the proportionality of economic evaluation. Ex-
plicit declaration of known limitations in the submitted
economic evaluation is also not a regular part of critical
appraisal checklists; the Hungarian checklist addresses
this issue. According to Ramsberg et al. [19], checklists
tend to be too general to pick up fine distinctions of spe-
cific models.
A limitation of the Hungarian Critical Appraisal
Checklist could be that its development is based on the
reappraisal of only 50 submissions, and thus may not re-
flect all potential problems. The Hungarian checklist
does not employ a scoring system; consequently it can-
not rank different economic evaluations quantitatively.
Unless items are explicitly weighted, the implicit general
assumption is that all questions are treated as equally
important [28]. Compared with previous checklists with
a scoring system, the Hungarian Critical Appraisal
Checklist, as a qualitative tool, could not be validated
with statistical methods. Certain steps of the methodo-
logical approach employed in this research were similar
to methods in previous publications. Gerkens et al. [22]
appraised nine economic evaluations to compare three
different checklists (British Medical Journal (BMJ)
checklist, Consensus Health Economic Criteria (CHEC)
list, Quality of Health Economic Studies (QHES) grading
system). The development of a scoring system by
Gonzalez-Perez [23] was based on a 50-study sample.
Ramsberg et al. [19] scrutinized a sample of 20 submis-
sions in Sweden (2002-2003). Similarly to our approach,
these studies applied at least two independent reviewers.
A further development of the Hungarian checklist
could be to assign weights to each question. However,
the aim of this checklist is not to score submissions by
counting the number of “yes” answers, but to avoid
methodological and technical errors in future submis-
sions by using this instrument when compiling
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checklist is based on current Hungarian practice, the
authors could dedicate questions only to those problems
that occurred in the 50 assessed HTA documents. The
authors recommend that the checklist be revised period-
ically, approximately every two years. Continuous devel-
opment of the checklist can prevent to be grounded in
the current methodology. E.g. the current methodo-
logical guidelines for economic evaluations in Hungary
does not necessitate the use of probabilistic sensitivity
analysis (PSA), once it becomes recommended, the
checklist can be extended with new items on PSAs. As
the Hungarian methodological guidelines determine nor-
mative aspects of economic analyses and some of these
items (e.g. discount rate, cost effectiveness threshold) are
subject to change in the forthcoming guidelines, the crit-
ical appraisal checklist does not mention any normative
aspects to ensure full harmonisation with the guidelines.
Conclusions
The new Hungarian Critical Appraisal Checklist is
detailed enough to address the most common problems
in local economic evaluations and budget impact ana-
lyses submitted in reimbursement dossiers by pharma-
ceutical companies. The published checklist will be used
officially by the HTA Office in the pharmaceutical’s sin-
gle health technology assessment process. As it will be
in the public domain, application of the checklist should
improve the consistency of the appraisal process and
consequently encourage pharmaceutical companies to
assure the quality of their submitted economic evalua-
tions. Overall, the use of a transparent method of single
technology assessment should improve the appropriate-
ness of pharmaceutical reimbursement decisions.
The authors believe that the Hungarian Critical Ap-
praisal Checklist will prove to be a significant step towards
the better use of economic evaluations in the reimburse-
ment of pharmaceuticals and by adopting the develop-
ment methodology or certain questions, may have policy
implications for several other Central-Eastern European
middle income countries. It is noteworthy, especially in
Central-Eastern Europe, that a public authority has been
willing to develop and publish scientifically rigorous cri-
teria for decision-making purposes. We are not aware of
any published critical appraisal checklists specifically
developed for pharmaceuticals based on the HTA practice
and skill set of middle income countries.
Additional file
Additional file 1: Hungarian critical appraisal checklist.
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